Pharma Deals Watch: Coverage Initiated on AstraZeneca, Advaxis, Radius Health, Cubist and AbbVie

NEW YORK, December 22, 2014 /PRNewswire/ --

Moments ago, Analysts Review released new research updates concerning several important developing situations including AstraZeneca (NYSE: AZN), Advaxis (NASDAQ: ADXS), Radius Health (NASDAQ: RDUS), Cubist (NASDAQ: CBST), and AbbVie (NYSE: ABBV). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.

To access our full PDF reports on a complementary basis, please visit the links below.

--

Today's update concerns the following companies:

============

Full PDF Download Links (you may have to copy and paste the following links into your browser):

AZN Research Report: ( http://get.analystsreview.com/pdf/?c=AstraZeneca&d=22-Dec-2014&s=AZN ),

ADXS Research Report: ( http://get.analystsreview.com/pdf/?c=Advaxis&d=22-Dec-2014&s=ADXS ),

RDUS Research Report: ( http://get.analystsreview.com/pdf/?c=Radius%20Health&d=22-Dec-2014&s=RDUS ),

CBST Research Report: ( http://get.analystsreview.com/pdf/?c=Cubist&d=22-Dec-2014&s=CBST ),

ABBV Research Report: ( http://get.analystsreview.com/pdf/?c=AbbVie&d=22-Dec-2014&s=ABBV ).

============

--

Analyst Update: FDA Approval, Financing Agreement, andPositive Study Results

Reviewed by: Rohit Tuli, CFA®  

The U.S. markets extended their gains for a third session on Friday with the S&P 500 adding up its second best week in almost two years. The Dow Jones Industrial Average finished at 17,804.80, up 0.15%, the NASDAQ Composite edged 0.36% higher at 4,765.38, and the S&P 500 advanced 0.46% to close the session at 2,070.65. The rally in the U.S. stocks was fueled by the Federal Reserve's assurance on Wednesday to take a patient approach towards raising interest rates, which calmed the investors over the policy outlook. On the other hand, the European markets ended Friday's session on a mixed note as Italian banking and healthcare stocks weighed down the wider benchmarks. The Asian markets extended the previous day's gain on Friday and ended on a positive note boosted by the momentum on Wall Street following the reassurance from Federal Reserve that interest rates would be hiked no sooner than mid-2015.

AstraZeneca plc (AstraZeneca) announced that its ovarian cancer drug, Lynparza, has been granted an accelerated approval by the US Food and Drug Administration (FDA). The development came a day after the Company's Lynparza received Marketing Authorization from the European Commission (EC). Find out more about AstraZeneca's latest regulatory approval for Lynparza.

Shares of Advaxis, Inc. (Advaxis) jumped over 15% on Friday, December 19, after the Company announced that it raised approx. $16.7 million through a definitive securities purchase agreement with two institutional investors. As per the deal, the Company placed approximately 3.9 million shares at a price of $4.25 per share. Find out more about the Company's financing agreement and how it plans to use the issue proceeds.

Radius Health Inc. (Radius) announced that its investigational drug for reduction of fractures in postmenopausal osteoporosis met the primary endpoint in a Phase 3 clinical trial (ACTIVE). The drug, abaloparatide-SC, met the primary goal of the study by achieving a statistically significant 83% reduction of incident vertebral fractures as compared to the placebo-treated group. Find out more about results of Radius' ACTIVE pivotal Phase 3 fracture prevention trial for the investigational drug abaloparatide-SC by clicking on our research report below.

Cubist Pharmaceuticals Inc. (Cubist) announced that the U.S. health regulator has approved its ZERBAXA that addresses certain serious and resistant Gram-negative bacteria. ZERBAXA is the first new antibiotic approved in the U.S. under the Generating Antibiotic Incentives Now (GAIN) Act to treat Gram-negative bacteria. Click on the report below to know more about the approval for Cubist's ZERBAXA in the battle against Gram-negative bacteria, where few treatment options exist.

AbbVie Inc. (AbbVie) announced that its VIEKIRA PAK has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection, including those with compensated cirrhosis. Currently, HCV is affecting more than 3.2 million Americans, which is nearly three times as many people affected by the human immunodeficiency virus (HIV). Find out more about the AbbVie's new Hepatitis C drug and its deal with nation's largest pharmacy benefit manager.

--

About Analysts Review  

At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.

--

Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.

Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED